Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
156actual
Sites
113
Countries
Algeria, Australia, Bosnia and Herzegovina +30
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-13 | actual | When the study began enrolling |
| Primary completion | 2022-07-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-21 | estimated | The whole study's end, after follow-up |
| First posted | 2019-09-09 | actual | When this record first appeared on the registry |
| Results posted | 2025-10-31 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Haemophilia A Without Inhibitors
- Haemophilia B Without Inhibitors
Intervention
- Drug: Concizumab
Primary outcomes
what the primary-completion date above is the date OFHaemophilia A Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding Episodes
measured On demand (arm 1): From week 0 up until start of concizumab treatment (week 24); Concizumab (arm 2): From week 0 up until the confirmatory analyses cut-off
Haemophilia B Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding Episodes
measured On demand (arm 1): From week 0 up until start of concizumab treatment (week 24); Concizumab (arm 2): From week 0 up until the confirmatory analyses cut-off
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2021-03-25 · 2.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-08-04 · 509 KB · SAP_001.pdf
Publications
- PMID 42341325 — linked by the registry
- PMID 40166710 — linked by the registry
- PMID 39521008 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed